Acute-on-Chronic Liver Failure (ACLF) is a syndrome in cirrhosis that is characterized by acute decompensation (AD), organ failure(s), and high short-term mortality.&nbsp;
&nbsp;
Type-A ACLF is an acute worsening of liver function in a patient with chronic liver disease. Type-B ACLF occurs when this acute decompensation occurs in patients with cirrhosis, while type-C ACLF is an acute worsening of liver functions in decompensated cirrhotics.
&nbsp;
Acute-on-Chronic Liver Failure Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Acute-on-Chronic Liver Failure in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Cases of Acute-on-chronic liver failure</li>
<li>Cases of Acute-on-Chronic Liver Failure by Grades</li>
<li>Organ failures associated with Acute-on-Chronic Liver Failure</li>
<li>Potential precipitating events of Acute-on-Chronic Liver Failure</li>
</ul>
&nbsp;
Acute-on-Chronic Liver Failure Epidemiology&nbsp;
<ul>
<li>The total population of Acute-on-Chronic Liver Failure in 7MM was 60,521 cases in 2017.&nbsp;</li>
<li>Grade-wise of Acute-on-Chronic Liver Failure prevalent cases in 2017</li>
<li class="ql-indent-1">Grade 1- 6,089&nbsp;&nbsp;</li>
<li class="ql-indent-1">Grade 2- 4,810&nbsp;</li>
<li class="ql-indent-1">Grade 3 -1,677&nbsp;&nbsp;</li>
<li>The population of ACLF cases in the United States was 12,577 in 2017.&nbsp;</li>
</ul>
&nbsp;
<a style="color: #0066cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market" target="_blank" rel="noopener noreferrer">Acute-on-Chronic Liver Failure Market</a>
The therapeutic market of Acute-on-Chronic Liver Failure (ACLF) in 7MM in 2017 was USD 70.55 million.&nbsp;
&nbsp;
Acute-on-Chronic Liver Failure Market Drivers
<ul>
<li>Absence of curative and disease-specific treatment options</li>
<li>Progress in the understanding of disease</li>
<li>Innovative therapeutic approaches&nbsp;</li>
</ul>
&nbsp;
Acute-on-Chronic Liver Failure Market Barriers
<ul>
<li>Lack of epidemiology data</li>
<li>Need for standard diagnostic criteria</li>
<li>Uncertainty related to cell-based therapies&nbsp;</li>
</ul>
&nbsp;
Acute-on-Chronic Liver Failure Emerging Drugs&nbsp;
The Emerging Drugs of the Acute-on-Chronic Liver Failure market are&nbsp;
<ul>
<li>Albutein (PE-A 5%)</li>
<li>HepaStem</li>
</ul>
And many others.&nbsp;
&nbsp;
Other Promising Acute-on-Chronic Liver Failure Candidates
<ul>
<li>APZ2</li>
<li>VS-01</li>
<li>Livantra</li>
</ul>
&nbsp;
Acute-on-Chronic Liver Failure Key Players
The key players in the Acute-on-Chronic Liver Failure market are
<ul>
<li>Grifols Therapeutics</li>
<li>Promethera Biosciences</li>
<li>RHEACELL</li>
<li>Versantis</li>
<li>Martin Pharmaceuticals&nbsp;</li>
</ul>
And many others.&nbsp;

Acute on Chronic Liver Failure Market

Acute on Chronic Liver Failure Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.